24.31
-0.62 (-2.49%)
| Penutupan Terdahulu | 24.93 |
| Buka | 25.00 |
| Jumlah Dagangan | 169,083 |
| Purata Dagangan (3B) | 1,029,941 |
| Modal Pasaran | 2,130,618,240 |
| Harga / Pendapatan (P/E Ke hadapan) | 4.65 |
| Harga / Jualan (P/S) | 314.42 |
| Harga / Buku (P/B) | 2.29 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Operasi (TTM) | -5,147.81% |
| EPS Cair (TTM) | -3.65 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 78.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.54% |
| Nisbah Semasa (MRQ) | 13.92 |
| Aliran Tunai Operasi (OCF TTM) | -264.11 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -164.58 M |
| Pulangan Atas Aset (ROA TTM) | -21.84% |
| Pulangan Atas Ekuiti (ROE TTM) | -31.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | IDEAYA Biosciences, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 2.13 |
|
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.90% |
| % Dimiliki oleh Institusi | 117.09% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 72.00 (JP Morgan, 196.17%) | Beli |
| Median | 44.00 (81.00%) | |
| Rendah | 30.00 (RBC Capital, 23.41%) | Beli |
| Purata | 48.67 (100.21%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 23.43 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JP Morgan | 28 Jul 2025 | 72.00 (196.17%) | Beli | 25.02 |
| RBC Capital | 09 Jul 2025 | 30.00 (23.41%) | Beli | 22.97 |
| Wells Fargo | 26 Jun 2025 | 44.00 (81.00%) | Beli | 22.29 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |